Chugai Pharmaceutical Co., Ltd.
Bear Case (25th pct.)
-57.0% vs price
Base Case (Median)
-48.5% vs price
Bull Case (75th pct.)
-40.2% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $1640.09 | -78.0% | High (40%) |
| PE Comparable | $6085.42 | -18.3% | Medium (25%) |
| Growth Trajectory DCF | $4306.22 | -42.2% | Medium (20%) |
| Graham Number | $2758.70 | -63.0% | Medium (40%) |
| EV/EBITDA | $3836.56 | -48.5% | Medium (20%) |
| EV/FCF | $4601.73 | -38.2% | Medium (20%) |
| Earnings Power Value | $3646.21 | -51.1% | Medium (50%) |
Based on 7 out of 8 methods, 4519.T appears overvalued at the current price of $7450.00. The base case fair value of $3836.56 implies 48.5% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.